Performance of PCR/Electrospray Ionization-Mass Spectrometry on Whole Blood for Detection of Bloodstream Microorganisms in Patients with Suspected Sepsis

Strålin, Kristoffer; Rothman, Richard E.; Özenci, Volkan; Barkataki, Kieron; Brealey, David; Dhiman, Neelam; Poling, Lara; Kurz, Michael C.; Limaye, Ajit P.; LoVecchio, Frank; Lowery, Kristin S.; Miller, Loren G.; Moran, Gregory J.; Overcash, J. Scott; Parekh, A.; Peacock, W. Frank; Rivers, Emanuel P.; Sims, Matthew; Stubbs, Amy; Sundqvist, Martin; Ullberg, Måns; Carroll, Karen C.

doi:10.1128/jcm.01860-19

Cited by 9 publications

(3 citation statements)

References 30 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MALDI-TOF MS (matrix-assisted laser desorption ionization coupled with time-of-flight analysis mass spectrometry) is based on a soft laser ionization of bacteria, or even of the pathological sample, to detect peptide and protein ions of the bacteria cell surfaces through the spectra deriving from their relative masses and charges [100]. The PCR-electrospray ionization (ESI)/MS (Ibis) technique is interestingly founded on nucleotide base ratios (not base sequences) [101].…”

Section: Bacteria Detection In Biofilmsmentioning

confidence: 99%

Emerging Issues and Initial Insights into Bacterial Biofilms: From Orthopedic Infection to Metabolomics

Mirzaei,

Campoccia,

Ravaioli

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Bacterial biofilms, enigmatic communities of microorganisms enclosed in an extracellular matrix, still represent an open challenge in many clinical contexts, including orthopedics, where biofilm-associated bone and joint infections remain the main cause of implant failure. This study explores the scenario of biofilm infections, with a focus on those related to orthopedic implants, highlighting recently emerged substantial aspects of the pathogenesis and their potential repercussions on the clinic, as well as the progress and gaps that still exist in the diagnostics and management of these infections. The classic mechanisms through which biofilms form and the more recently proposed new ones are depicted. The ways in which bacteria hide, become impenetrable to antibiotics, and evade the immune defenses, creating reservoirs of bacteria difficult to detect and reach, are delineated, such as bacterial dormancy within biofilms, entry into host cells, and penetration into bone canaliculi. New findings on biofilm formation with host components are presented. The article also delves into the emerging and critical concept of immunometabolism, a key function of immune cells that biofilm interferes with. The growing potential of biofilm metabolomics in the diagnosis and therapy of biofilm infections is highlighted, referring to the latest research.

show abstract

Section: Bacteria Detection In Biofilmsmentioning

confidence: 99%

Emerging Issues and Initial Insights into Bacterial Biofilms: From Orthopedic Infection to Metabolomics

Mirzaei,

Campoccia,

Ravaioli

et al. 2024

Antibiotics

View full text Add to dashboard Cite

show abstract

“…Unfortunately, systems using PCR/electrospray ionization-mass spectrometry (e.g. Abbott IRIDICA), with the capacity to replicate the range of detection provided by culture, but with greater sensitivity when directly testing a range of samples, appear to be currently unavailable [ 131 – 135 ]. Other broad-ranging approaches (e.g.…”

Section: Molecular Detection Of Yeasts Other Than Candidamentioning

confidence: 99%

Molecular Diagnosis of Yeast Infections

White

Price

Cordey

et al. 2021

Curr Fungal Infect Rep

View full text Add to dashboard Cite

Purpose of Review The use of molecular tests to aid the diagnosis of invasive yeast infection, in particular invasive candidosis, has been described for over two decades, yet widespread application is limited, and diagnosis remains heavily dependent on classical microbiology. This article will review developments from the past decade in attempt to build on existing knowledge. It will highlight clinical performance and limitations while reviewing developments on recognized procedures; it will also provide insight into novel approaches incorporated in response to clinical demand (e.g. C. auris and antifungal resistance) or technological advances (e.g. next-generation sequencing). Recent Findings Limited methodological standardization and, until recently, unavailability of commercial options have hindered the integration of molecular diagnostics for yeasts. The development of certain, novel commercial methods has received considerable evaluation allowing a greater understanding of individual assay performance, but widespread multicentre evaluation of most commercial kits is lacking. The detection of emerging pathogens (e.g. C. auris ) has been enhanced by the development of molecular tests. Molecular methods are providing a better understanding of the mycobiome, mechanisms of resistance and epidemiology/phylogeny. Summary Despite over two decades of use, the incorporation of molecular methods to enhance the diagnosis of yeast infections remains limited to certain specialist centres. While the development of commercial tests will provide stimulus for broader application, further validation and reduced costs are required. Over the same period of time, Aspergillus PCR has become more widely accepted driven by international efforts to standardize methodology; it is critical that yeast PCR follows suit. Next-generation sequencing will provide significant information on the mycobiome, antifungal resistance mechanism and even broad-range detection directly from the specimen, which may be critical for the molecular detection of yeasts other than Candida species, which is currently limited.

show abstract

“…With the first successful application of metagenomics next-generation sequencing (mNGS) in clinical infection of the central nervous system (CNS) ( 17 ), this unbiased technology has been extensively used to detect pathogens in various infections ( 18 – 20 ). Although the pathogen loads were higher in neonates ( 21 ) than in adults ( 22 , 23 ), the volumes of samples obtained from neonates were lower than those obtained from adults ( 24 ), which seriously hindered the accurate detection of pathogens ( 25 ). The above-mentioned problems raised the question of how to accurately detect pathogens from neonatal samples with limited volumes using mNGS.…”

Section: Introductionmentioning

confidence: 99%

Metagenomic Next-Generation Sequencing for the Diagnosis of Neonatal Infectious Diseases

et al. 2022

View full text Add to dashboard Cite

To the best of our knowledge, this is the first report on evaluating the performance of mNGS using cfDNA and RNA from body fluid and blood samples for diagnosing neonatal infections. mNGS of RNA and cfDNA can achieve the unbiased detection and identification of trace pathogens from different kinds of neonatal body fluid and blood samples with a high total coincidence rate (226/331; 68.3%) against final clinical diagnoses by sample. The best timing for mNGS detection in neonatal infections ranged from 1 to 3 days, rather than 0 days, after the start of continuous antimicrobial therapy.

show abstract

Performance of PCR/Electrospray Ionization-Mass Spectrometry on Whole Blood for Detection of Bloodstream Microorganisms in Patients with Suspected Sepsis

Cited by 9 publications

References 30 publications

Emerging Issues and Initial Insights into Bacterial Biofilms: From Orthopedic Infection to Metabolomics

Emerging Issues and Initial Insights into Bacterial Biofilms: From Orthopedic Infection to Metabolomics

Molecular Diagnosis of Yeast Infections

Metagenomic Next-Generation Sequencing for the Diagnosis of Neonatal Infectious Diseases

Contact Info

Product

Resources

About